Amicus Therapeutics maintains 2 "hold" and 4 "buy" ratings from major analyst firms.
Needham & Company LLC reaffirmed its "hold" rating for Amicus Therapeutics (NASDAQ:FOLD). JPMorgan Chase & Co. cut their price target from $21.00 to $19.00 with an "overweight" rating, Bank of America lowered the target price from $14.00 to $13.00 with a "buy" rating, and Cantor Fitzgerald maintained an "overweight" rating with a $22.00 price target. The company currently has 2 "hold" and 4 "buy" ratings, according to MarketBeat.com.
May 10, 2024
4 Articles